175 related articles for article (PubMed ID: 23761054)
1. Diclofenac enables unprecedented week-long microneedle-enhanced delivery of a skin impermeable medication in humans.
Brogden NK; Banks SL; Crofford LJ; Stinchcomb AL
Pharm Res; 2013 Aug; 30(8):1947-55. PubMed ID: 23761054
[TBL] [Abstract][Full Text] [Related]
2. Development of a codrug approach for sustained drug delivery across microneedle-treated skin.
Ghosh P; Pinninti RR; Hammell DC; Paudel KS; Stinchcomb AL
J Pharm Sci; 2013 May; 102(5):1458-67. PubMed ID: 23417751
[TBL] [Abstract][Full Text] [Related]
3. Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin.
Banks SL; Paudel KS; Brogden NK; Loftin CD; Stinchcomb AL
Pharm Res; 2011 May; 28(5):1211-9. PubMed ID: 21301935
[TBL] [Abstract][Full Text] [Related]
4. Diclofenac delays micropore closure following microneedle treatment in human subjects.
Brogden NK; Milewski M; Ghosh P; Hardi L; Crofford LJ; Stinchcomb AL
J Control Release; 2012 Oct; 163(2):220-9. PubMed ID: 22929967
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of skin resealing after insertion of microneedles in human subjects.
Gupta J; Gill HS; Andrews SN; Prausnitz MR
J Control Release; 2011 Sep; 154(2):148-55. PubMed ID: 21640148
[TBL] [Abstract][Full Text] [Related]
6. Optimization of naltrexone diclofenac codrugs for sustained drug delivery across microneedle-treated skin.
Ghosh P; Lee D; Kim KB; Stinchcomb AL
Pharm Res; 2014 Jan; 31(1):148-59. PubMed ID: 23943543
[TBL] [Abstract][Full Text] [Related]
7. Fluvastatin as a micropore lifetime enhancer for sustained delivery across microneedle-treated skin.
Ghosh P; Brogden NK; Stinchcomb AL
J Pharm Sci; 2014 Feb; 103(2):652-60. PubMed ID: 24395718
[TBL] [Abstract][Full Text] [Related]
8. Novel nano-in-micro fabrication technique of diclofenac nanoparticles loaded microneedle patches for localised and systemic drug delivery.
Li M; Vora LK; Peng K; Sabri AHB; Qin N; Abbate M; Paredes AJ; McCarthy HO; Donnelly RF
Biomater Adv; 2024 Jul; 161():213889. PubMed ID: 38781739
[TBL] [Abstract][Full Text] [Related]
9. Effect of microporation on passive and iontophoretic delivery of diclofenac sodium.
Patel H; Joshi A; Joshi A; Stagni G
Drug Dev Ind Pharm; 2015; 41(12):1962-7. PubMed ID: 25758411
[TBL] [Abstract][Full Text] [Related]
10. Micropore closure kinetics are delayed following microneedle insertion in elderly subjects.
Kelchen MN; Siefers KJ; Converse CC; Farley MJ; Holdren GO; Brogden NK
J Control Release; 2016 Mar; 225():294-300. PubMed ID: 26829102
[TBL] [Abstract][Full Text] [Related]
11. Micropore Closure Rates following Microneedle Application at Various Anatomical Sites in Healthy Human Subjects.
Ogunjimi AT; Lawson C; Carr J; Patel KK; Ferguson N; Brogden NK
Skin Pharmacol Physiol; 2021; 34(4):214-228. PubMed ID: 33910205
[TBL] [Abstract][Full Text] [Related]
12. Development of in vivo impedance spectroscopy techniques for measurement of micropore formation following microneedle insertion.
Brogden NK; Ghosh P; Hardi L; Crofford LJ; Stinchcomb AL
J Pharm Sci; 2013 Jun; 102(6):1948-1956. PubMed ID: 23589356
[TBL] [Abstract][Full Text] [Related]
13. Micropore closure time is longer following microneedle application to skin of color.
Ogunjimi AT; Carr J; Lawson C; Ferguson N; Brogden NK
Sci Rep; 2020 Nov; 10(1):18963. PubMed ID: 33144596
[TBL] [Abstract][Full Text] [Related]
14. Naltrexone salt selection for enhanced transdermal permeation through microneedle-treated skin.
Milewski M; Pinninti RR; Stinchcomb AL
J Pharm Sci; 2012 Aug; 101(8):2777-86. PubMed ID: 22628183
[TBL] [Abstract][Full Text] [Related]
15. Impact of Formulation and Microneedle Length on Transdermal Metronidazole Permeation through Microneedle-Treated Skin.
Patel KK; Brogden NK
Pharm Res; 2024 Feb; 41(2):355-363. PubMed ID: 38133717
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and in vitro stability of amino acid prodrugs of 6-β-naltrexol for microneedle-enhanced transdermal delivery.
Eldridge JA; Milewski M; Stinchcomb AL; Crooks PA
Bioorg Med Chem Lett; 2014 Nov; 24(22):5212-5. PubMed ID: 25442314
[TBL] [Abstract][Full Text] [Related]
17. Effect of formulation pH on transport of naltrexone species and pore closure in microneedle-enhanced transdermal drug delivery.
Ghosh P; Brogden NK; Stinchcomb AL
Mol Pharm; 2013 Jun; 10(6):2331-9. PubMed ID: 23590208
[TBL] [Abstract][Full Text] [Related]
18. Vehicle composition influence on the microneedle-enhanced transdermal flux of naltrexone hydrochloride.
Milewski M; Stinchcomb AL
Pharm Res; 2011 Jan; 28(1):124-34. PubMed ID: 20577787
[TBL] [Abstract][Full Text] [Related]
19. Current aspects of formulation efforts and pore lifetime related to microneedle treatment of skin.
Milewski M; Brogden NK; Stinchcomb AL
Expert Opin Drug Deliv; 2010 May; 7(5):617-29. PubMed ID: 20205604
[TBL] [Abstract][Full Text] [Related]
20. Novel 3-O-pegylated carboxylate and 3-O-pegylated carbamate prodrugs of naltrexone for microneedle-enhanced transdermal delivery.
Yerramreddy TR; Milewski M; Penthala NR; Stinchcomb AL; Crooks PA
Bioorg Med Chem Lett; 2010 Jun; 20(11):3280-3. PubMed ID: 20451376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
